Incyte’s cancer drug fails trial, marking major blow for immunotherapy combination treatment – STAT
STAT |
Incyte's cancer drug fails trial, marking major blow for immunotherapy combination treatment
STAT he first real clinical test of the cancer immunotherapy combination thesis has come back negative. Incyte said Friday that its experimental drug epacadostat failed to improve the efficacy of Merck's checkpoint inhibitor Keytruda when the two drugs were … Incyte tumbles after combo therapy with Merck fails study Incyte slumps 19% after combo therapy fails late-stage test Incyte, Merck & Co. Halt Phase III Trial After Epacadostat/Keytruda Combination Fails in Melanoma |
